The Serum Protein and Lipid Oxidation Marker Levels in Alzheimer's Disease and Effects of Cholinesterase Inhibitors and Antipsychotic Drugs Therapy

Publisher： Bentham Science Publishers

E-ISSN： 1875-5828|7|5|463-469

ISSN： 1567-2050

Source： Current Alzheimer Research, Vol.7, Iss.5, 2010-08, pp. : 463-469

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimer's Disease: A Review of Recent Clinical Studies

By  

Current Alzheimer Research, Vol. 7, Iss. 1, 2010-02 ,pp. : 67-73

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimer's Disease Pharmacogenetics

By  

Current Alzheimer Research, Vol. 4, Iss. 4, 2007-09 ,pp. : 479-500

Bentham Science Publishers

Access to resources Recommend Favorite

Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors

By  

Current Alzheimer Research, Vol. 15, Iss. 11, 2018-09 ,pp. : 1077-1084

Bentham Science Publishers

Access to resources Recommend Favorite

Cholinesterase inhibitors in Alzheimer's disease: a consensus view on managing treatment failure

By Emre Murat   Farlow Martin   Bullock Roger   Gauthier Serge   Grossberg George   Potkin Steven G  

Primary Care Psychiatry, Vol. 9, Iss. 1, 2004-01 ,pp. : 29-30

Informa Healthcare

Access to resources Recommend Favorite

Cholinesterase inhibitors in Alzheimer’’s disease: sooner or later or both?

By Kerwin Robert  

Future Neurology, Vol. 1, Iss. 6, 2006-11 ,pp. : 737-740

Future Medicine

Access to resources Recommend Favorite